Long-Term Survivors of Glioblastoma

• Long-term glioblastoma survival
• The reality of survival statistics
• Managing long-term side effects
• How does genetic makeup of a tumor impact survival?
• MGMT in long-term glioblastoma survival
• IDH in long-term glioblastoma survival
• Tumor recurrence
• Working towards a cure

Glioblastoma is the most aggressive type of brain tumor and is brain cancer. However, a small group of patients survive 5, 10, and even 20 years after initial diagnosis.

Younger patients with good health at diagnosis and those with favorable tumor genetics (MGMT promoter methylation and IDH mutations, specifically) tend to survive longer.

Although the average life expectancy after a diagnosis of glioblastoma is between 14 and 16 months, patients with certain tumor genetics have a median survival time of 22 and 31 months.

The longest glioblastoma survivor has lived for more than 20 years after diagnosis. While long-term survivors have been documented, these cases are uncommon.

Here, we will shed some light on what factors impact glioblastoma survival in patients with glioblastoma to provide a realistic outlook on prognosis.

Glioblastoma, also known as grade IV astrocytoma, is the most aggressive type of brain tumor. This devastating disease is infamous for taking the lives of many patients, with special media attention focusing on politicians, artists, scientists, and entrepreneurs. The voices of long-term survivors are often less widely heard.

Although the average life expectancy after diagnosis is 14 to 16 months, approximately 1% of patients survive at least 10 years. Currently, the longest anyone has survived a glioblastoma is more than 20 years and counting.

But what makes this small group of glioblastoma patients so special? Researchers are investigating differences between glioblastoma patients who survive for long periods of time and those who unfortunately succumb early to the disease.

Several factors appear to come into play. A younger age (20 – 40 years old) and good functional status at diagnosis are associated with longer survival. Surprisingly, some of the strongest factors for prolonged survival come from the genetic makeup of the tumor.

Receiving a glioblastoma diagnosis can be overwhelming, and patient survival rates are crucial for providing context to the path ahead. 

As mentioned earlier, the median survival rate of glioblastoma patients stands at around 14 to 16 months following diagnosis. However, it’s worth emphasizing that these are medians, and individual experiences can differ significantly. In fact, around 6.9% of patients reach the five-year survival mark. This figure demonstrates that, although rare, glioblastoma long-term survivors do exist.  

For long-term survivors of glioblastoma, the journey involves learning to manage the side effects that may persist or arise as a result of the disease or its treatment. These can include headaches, seizures, cognitive or motor skill impairment, and emotional changes. It is crucial to maintain open lines of communication with healthcare professionals to monitor these effects, adjust care plans accordingly and maintain the quality of life. 

Support groups and counseling can also benefit glioblastoma long-term survivors and their families by helping them adapt to these changes over the long term. Rehabilitative services and therapies can also promote the highest possible quality of life. 

While the path ahead may be challenging, long-term glioblastoma survivors exemplify that life beyond diagnosis is possible. Ultimately, professional, empathetic and personalized care can make a meaningful difference in helping patients live their lives to the fullest, hopefully extending periods of remission and making each day as fulfilling as possible. 

Although glioblastomas have some genetic changes in common, no glioblastoma tumor is identical. In fact, some glioblastomas may have genetic changes that make current therapies work better. The most widely known genetic mutations are in the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) and an enzyme involved in metabolism called isocitrate dehydrogenase (IDH).

MGMT is a DNA repair enzyme normally found in healthy cells. MGMT is usually a beneficial enzyme. It helps repair your DNA when it becomes damaged by the environment, toxins, and other exposures in your everyday life.

While MGMT is normally a good thing in healthy cells, it is a bad thing in tumor cells. Chemotherapy used to treat glioblastomas (such as Temodar) damages tumor DNA in an attempt to signal cell death. MGMT in a tumor cell prevents this chemotherapy from working as well. This causes treatments to be less effective.

In some glioblastomas, there are low levels of MGMT due to a phenomenon called “promoter methylation”. A promoter is a sequence of DNA that can turn a gene on or off.

When a carbon and three hydrogen atoms (methyl group) are transferred to parts of the promotor in a process called methylation, this usually turns the gene off. Therefore, MGMT promoter methylation prevents the enzyme (MGMT) from being created by tumor cells.

Glioblastoma MGMT promoter methylation is positive news. This means that the MGMT gene is making less of the DNA repair enzyme (MGMT) for the tumor to use against chemotherapy treatment. The tumor will have a difficult time repairing itself and is more likely to shrink following chemotherapy with medications, such as Temodar.

Patients with tumors that have MGMT promoter methylation are reported to survive longer (with a median survival time of 22 months) compared to those without MGMT promoter methylation (a median survival of between 14 to 16 months).

IDH is an enzyme involved in the biochemical breakdown of foods to energy and the creation of other important products for the cell (metabolism).

Mutations in IDH are commonly seen in glioblastomas that have evolved from a glioma of a lower grade, such as a grade II or III astrocytoma or oligodendroglioma.

Having an IDH mutation in the tumor is favorable for the patient, as it impairs the tumor’s metabolism and slows growth. Patients with glioblastoma carrying an IDH1 or IDH2 mutation have a longer median survival time of 31 months.

Unfortunately, many glioblastomas recur. The recurrent tumor is usually of the same type and often retains most of the genetic makeup from the initial tumor.

They most commonly appear less than 2 cm from the initial tumor site but can arise in more distant locations. Since the recurrent tumor shares many similarities with the initial glioblastoma, the treatments will also be very similar.

Researchers are actively testing new therapies to treat glioblastoma. Experimental therapies include the use of anti-tumor antibodies for targeted destruction, vaccines to enhance the patient’s own immune system response, and gene therapy to deliver anti-cancer genes to the tumor. Speak to your physician about possible clinical trials that you could participate in.

Receiving the diagnosis of glioblastoma can be difficult to digest. Involve healthcare providers who will compassionately support you on your journey.

Although survival statistics are meant to provide factual historical data, each glioblastoma patient is different, and each day we make progress towards understanding this disease and broadening treatment options.

• National Brain Tumor Society
• American Brain Tumor Association
• Brain Tumor Foundation
• Children's Brain Tumor Foundation
• Pediatric Brain Tumor Foundation
• Glioblastoma Foundation